Daniel Von Hoff, M.D.

From Wikipedia, the free encyclopedia

Daniel D. Von Hoff, M.D. is a clinical oncologist and oncology drug developer who has conducted national clinical trials with more than 200 new antineoplastic and biologic agents, more than any other investigator. Over the past 20 years, he and his colleagues have conducted early clinical investigations of most of the new agents that have been approved for cancer treatment in the United States, including gemcitabine, docetaxel, paclitaxel, topotecan, irinotecan, fludarabine, mitoxantrone, and dexrazoxone.

Dr. Von Hoff is serving a six-year term on President Bush's National Cancer Advisory Board (June 2004 - March 2010) and has served on the FDA’s Oncology Advisory Committee. He is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.


Contents

[edit] Career

Dan Von Hoff has devoted his career to translational medicine, which is defined as movement of new therapies from the research institution into patient care. He currently serves as the Executive Vice President, Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division and heads its Pancreatic Cancer Research Program. He is also Professor of Medicine, Molecular and Cellular Biology and Pathology at the University of Arizona and served as director of the Arizona Cancer Center. He also serves as Chief Scientific Officer for US Oncology and the Scottsdale Clinical Research Institute. In addition, he provides expertise as a founder or medical/scientific advisor to a broad range of companies working toward a cure for cancer.

After graduating cum laude from Carroll College, Dr. Von Hoff received his M.D. from Columbia University College of Physicians and Surgeons. He completed his internship and residency in internal medicine at the University of California, San Francisco, then completed a medical oncology fellowship at the National Cancer Institute. Dr. Von Hoff then moved to the University of Texas at San Antonio, where he rose to Professor in the Department of Medicine and the Department of Cellular and Structural Biology. In 1989, Dr. Von Hoff became the Founding Director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio. In 1999, he became Director of the Cancer Center and Professor of Medicine at the University of Arizona.

Dr. Von Hoff has served as editor of numerous scientific publications. He is founder and Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents as well as the current Editor-in-Chief of Molecular Cancer Therapeutics. Previously he was the associate editor of Cancer Research and Clinical Cancer Research. Dr. Von Hoff has also served on the editorial boards of the American Journal of Medicine, Anticancer Drugs, Oncology, Annals of Oncology, and nine other scientific journals.

He is a Fellow of the American College of Physicians, and has been a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and AACR, as well as a member of the FDA's Oncology Drug Advisory Committee (ODAC).


[edit] Clinical Interests

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents used in cancer therapy, and he has published more than 529 papers, 129 book chapters, more than 891 abstracts and obtained several patents.

As the senior investigator at TGen, Dr. Von Hoff and his team are focused on targeted new anti-cancer agents. They currently have 26 new agents in phase I or II trials. The mechanisms of action in these agents is targeted toward specific abnormalities in a particular patient's tumor (individualized therapeutics). Their lab research is focused on genetic and biochemical approaches to identify molecular targets for the development of new therapies for patients with pancreatic cancer, which has the worst survival rate of any cancer and is the fourth leading cause of cancer deaths in the United States. Their approach is the development of targeted therapies based on distinguishing characteristics of pancreatic cancer cells versus normal cells.


[edit] Awards

Dr. Von Hoff is the recipient of numerous awards and honors for his patient care, teaching accomplishments and clinical investigation, including the University of Michigan Cancer Center 2003 Bull Award, the Ohio State University 2003 Block Award and The Weinberg Award, presented by the Dana Farber Cancer Center, Harvard Medical School. He has received the Frederick S. Philips Lectureship from Memorial Sloan-Kettering Cancer Center, the Michel Clavel Lectureship from the European Organization for Research and Treatment of Cancer (EORTC), and the Bagshawe Lectureship from the British Association for Cancer Research. In 1997, Dr. Von Hoff received the Richard and Hilda Rosenthal Foundation Award from AACR and was elected President of that organization for 1999-2000.


[edit] Scientific and Medical Advisory Roles

Dr. Von Hoff has founded and serves as a medical and scientific advisor to a broad range of companies working toward a cure for cancer, including


[edit] Publications

  • Wang, H., Han, H., Bearss, D., Von Hoff, D.D.. "A pharmacological synthetic lethal screening system for the identification of new anti-pancreatic cancer agents specifically targeting DPC4 deficient cells." Proc Am Assoc Cancer Res, 44:5489. 2003.
  • Han, H., Munoz, R.M., Bearss, D.J., Vankayalapati, H., Nagle, R.B., Hurley, L.H., Von Hoff, D.D.. "The urokinase-type plasminogen activator and its receptor as drug targets for pancreatic cancer." Proc Am Assoc Cancer Res, 44:5574. 2003.
  • Washingon, D., Miller, K., Budd, G.T., Taylor C., Von Hoff, D.D. , Brown, G.L., Parra, R., Jameson, A., Mascavage, J., Henner, W.D.. "Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) as > third-line therapy in patients with advanced metastatic breast cancer (MBC)." Proc Am Soc Clin Oncol, 22:61. 2003.
  • Von Hoff, D.D. , Jolivet, J., Steward, W.. "A dose-escalating phase I study of troxacitabine and gemcitabine in advanced solid malignancies." Proc Am Soc Clin Oncol, 22:566. 2003.
  • Garland, L.L., Gitlitz, B., Ebbinghaus, S., Gately, N., Trammell, J., Von Hoff, D.D. , Figlin, R.. "Phase I trial of intravenous IL-4 pseudomonas exotoxin (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor." Proc Am Soc Clin Oncol, 22:911. 2003.
  • Papadimitrakopoulou, V., Figlin, R., Garland, L., Blumenschein, G., Fossella, F., Von Hoff, D.D. , King, L., Brown, G.L., Mascavage, J., Henner, W.D.. "Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens." Proc Am Soc Clin Oncol, 22:2636. 2003.
  • Raymond, E., D. Sun, E. Izbicka, G. Mangold, E. Silvas, B. Windle, S. Sharma, H. Soda, R. Laurence, K. Davidson, and D.D. Von Hoff. 1999. "A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay." British Journal of Cancer 80: 1332-1341.
  • Sun, D., C.C. Lopez-Guajardo, J. Quada, L.H. Hurley, and D.D. Von Hoff. 1999. "Regulation of catalytic activity and processivity of human telomerase." Biochemistry 38: 4037-4044.
  • Izbicka, E., R.T. Wheelhouse, E. Raymond, K.K. Davidson, R.A. Lawrence, D. Sun, B.E. Windle, L.H. Hurley, and D.D. Von Hoff. 1999. "Effects of cationic porphyrins as G-Quadruplex interactive agents in human tumor cells." Cancer Research 59: 639-644.
  • Bearss, D.J., L.H. Hurley, and D.D. Von Hoff. 2000. "Telomere maintenance mechanisms as a target for drug development." Oncogene 19: 6632-6641.
  • Han, H., D.J. Bearss, L.W. Browne, R. Calaluce, R.B. Nagle, and D.D. Von Hoff. 2002. "Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray." Cancer Research 62: 2890-2896.
  • Von Hoff, D.D., and D. Bearss. 2002. "New drugs for patients with pancreatic cancer." Current Opinion in Oncology 14: 621-627.
  • Grand, C.L., H. Han, R.M. Munoz, S. Weitman, D.D. Von Hoff, L.H. Hurley, and D.J. Bearss. 2002. "The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo." Molecular Cancer Therapeutics 1: 565-573.
  • Vankayalapati, H., D.J. Bearss, J.W. Saldanha, R.M. Munoz, S. Rojanala, D.D. Von Hoff, and D. Mahadevan. 2003. "Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design." Molecular Cancer Therapeutics 2: 283-294.


[edit] References